ARTICLE | Product Development
Lilly-Vir mAb cocktail could expand treatment to low-risk COVID-19 patients
April 1, 2021 2:46 AM UTC
Top-line Phase II data for a combination of mAbs from Vir and Lilly could open the door to a mAb treatment for a new COVD-19 population: low-risk outpatients.
Three mAb therapies have emergency use authorization to treat COVID-19 in high-risk outpatients: bamlanivimab from Eli Lilly and Co. (NYSE:LLY) and AbCellera Biologics Inc. (NASDAQ:ABCL); the combination of bamlanivimab plus etesevimab, which Lilly developed with Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180); and the two-mAb cocktail REGEN-COV-2 from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)...